Kathleen Duryea
Family Medicine · Centre, ALNPI 1609881333
Payments from drug & device makers
Across 92 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$310
- AbbVie$160
- Lilly USA, LLC$139
- GSK$134
- AstraZeneca$123
- Merck$91
- plus $525 from 19 others
What the payments were for
- Food & beverage$1,482100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 17 | $310 |
| AbbVie | 14 | $160 |
| Lilly USA, LLC | 9 | $139 |
| GSK | 9 | $134 |
| AstraZeneca | 7 | $123 |
| Merck | 5 | $91 |
| Corium, LLC | 3 | $72 |
| Pfizer | 4 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Novo Nordisk | 3 | $41 |
| Amgen | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Atland Pharmaceuticals, LLC | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Redhill Biopharma Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Adlon Therapeutics L.p. | 1 | $12 |
How this compares
$1,482 in reported general payments places this provider in the 60th percentile of 1,680 family medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 27 | $23,914 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $19,331 |
| OzempicSemaglutide | 19 | $17,520 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $5,427 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,937 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 89 | $1,680 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,535 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 21 | $1,396 |
| Bupropion Hcl SrBupropion Hcl | 39 | $978 |
| Celecoxib | 24 | $910 |
| Duloxetine Hcl | 52 | $880 |
| Levothyroxine Sodium | 46 | $815 |
| Diclofenac Sodium | 33 | $761 |
| Atorvastatin Calcium | 50 | $744 |
| Metoprolol Succinate | 43 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $123 | $29,34147 claims |
| GSKTrelegy Ellipta | $134 | $19,33121 claims |
| Novo NordiskOzempic | $41 | $17,52019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Centre
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.